ArticleJournal of thrombosis and thrombolysis2014

Comparison of cost-effectiveness of anticoagulation with dabigatran, rivaroxaban and apixaban in patients with non-valvular atrial fibrillation across countries.

Martin Krejczy et al.PubMed ↗Publisher ↗

No numbers read from the abstract.